NAGI AYAD, PH.D.
Nagi G. Ayad, Ph.D. is a Professor in the Department of Oncology of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center. Dr. Ayad received his undergraduate degree from Rutgers University in 1992, worked for Merck & Co., Inc. as a biochemist and then pursued graduate studies with Dr. Ira Mellman at Yale University. Dr. Ayad completed his Ph.D. in Cell Biology in 1998 and moved to Harvard Medical School in 1999 to perform a postdoctoral fellowship with Dr. Marc Kirschner. Dr. Ayad then joined The Scripps Research Institute in Jupiter, Florida as an Assistant Professor in 2005 and moved to the University of Miami as an Associate Professor in 2011 and was promoted to Professor in 2021. He moved to LCCC in July 2021. Dr. Ayad’s research has focused on elucidating novel cell cycle pathways. His graduate studies identified a novel means through which endocytosis is inhibited during mitosis, while his postdoctoral studies identified two novel cell cycle regulators, Tome-1 and sororin. His work in his own laboratory has utilized high-throughput screens to identify regulators of cell cycle transitions, cancer, and ubiquitin-proteasome. These regulators include Wee1, Casein Kinase 1, the Anaphase Promoting Complex (APC/C), BRD4, and cereblon. He has a track record of developing novel small-molecule therapeutics for epigenetic and RNA binding proteins. His lab collaborates with a large group of basic scientists and clinicians to move small molecules into clinical trials.